{
      "Rank": 752,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.",
            "This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day."
      ],
      "ArmGroupInterventionName": [
            "Drug: Linagliptin",
            "Drug: Linagliptin"
      ],
      "ArmGroupLabel": [
            "Linagliptin patients with schizophrenia",
            "Linagliptin control group"
      ],
      "ArmGroupType": [
            "Active Comparator",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02442817"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of the present study is to gather pilot data on the effects of linagliptin on the concentration of the long and short forms of SDF1-\u03b1 (stromal cell-derived factor alpha) in humans, and to demonstrate the feasibility of such a study in patients with psychosis in our setting."
      ],
      "BriefTitle": [
            "Linagliptin and Mesenchymal Stem Cells: A Pilot Study"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "Augusta University"
      ],
      "CompletionDate": [
            "March 2, 2018"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Schizophrenia"
      ],
      "ConditionAncestorId": [
            "D000019967",
            "D000001523"
      ],
      "ConditionAncestorTerm": [
            "Schizophrenia Spectrum and Other Psychotic Disorders",
            "Mental Disorders"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BXM",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Behaviors and Mental Disorders",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Schizophrenia"
      ],
      "ConditionBrowseLeafId": [
            "M14528",
            "M13625",
            "M3967",
            "M20991"
      ],
      "ConditionBrowseLeafName": [
            "Schizophrenia",
            "Psychotic Disorders",
            "Mental Disorders",
            "Schizophrenia Spectrum and Other Psychotic Disorders"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000012559"
      ],
      "ConditionMeshTerm": [
            "Schizophrenia"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Non-Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Basic Science"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "This study is a 13-week, open-label study of 8 participants with schizophrenia and minimal thought disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment. The principal outcome measures will be the concentrations of the long and short forms of SDF1-\u03b1 (stromal cell-derived factor alpha) in blood."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMeets DSM (Diagnostic and Statistical Manual) criteria for schizophrenia.\nConsidered clinically stable, and on the same dose of antipsychotic for two weeks.\nA score no greater than 3 on the PANSS (Positive and Negative Syndrome Scale) Conceptual Disorganization item.\nNot taking any medications for diabetes, or any anti-inflammatories other than occasional aspirin or acetaminophen. Not taking Clozapine.\nAge 18-45 years.\nCan be available for regular morning appointments from 8:00 am to 10:00 am, preferably on Tuesdays, Wednesdays and Thursdays.\n\nExclusion Criteria:\n\nDoes not meet DSM criteria for substance abuse or dependence.\nNo serious current general medical condition, such as cancer, history of stroke or myocardial infarction, tuberculosis, HIV/AIDS, hemophilia, etc."
      ],
      "EnrollmentCount": [
            "10"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000007004",
            "D000045505",
            "D000054795",
            "D000006728",
            "D000006730",
            "D000054873",
            "D000011480",
            "D000004791",
            "D000045504"
      ],
      "InterventionAncestorTerm": [
            "Hypoglycemic Agents",
            "Physiological Effects of Drugs",
            "Incretins",
            "Hormones",
            "Hormones, Hormone Substitutes, and Hormone Antagonists",
            "Dipeptidyl-Peptidase IV Inhibitors",
            "Protease Inhibitors",
            "Enzyme Inhibitors",
            "Molecular Mechanisms of Pharmacological Action"
      ],
      "InterventionArmGroupLabel": [
            "Linagliptin control group",
            "Linagliptin patients with schizophrenia"
      ],
      "InterventionBrowseBranchAbbrev": [
            "CNSDep",
            "PsychDr",
            "All",
            "Hypo",
            "Infe"
      ],
      "InterventionBrowseBranchName": [
            "Central Nervous System Depressants",
            "Psychotropic Drugs",
            "All Drugs and Chemicals",
            "Hypoglycemic Agents",
            "Anti-Infective Agents"
      ],
      "InterventionBrowseLeafAsFound": [
            "VEGF"
      ],
      "InterventionBrowseLeafId": [
            "M16056",
            "M27110",
            "M445",
            "M9206",
            "M27058",
            "M8941",
            "M8940",
            "M13495",
            "M18761"
      ],
      "InterventionBrowseLeafName": [
            "Antipsychotic Agents",
            "Dipeptidyl-Peptidase IV Inhibitors",
            "Linagliptin",
            "Hypoglycemic Agents",
            "Incretins",
            "Hormones",
            "Hormone Antagonists",
            "Protease Inhibitors",
            "HIV Protease Inhibitors"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment."
      ],
      "InterventionMeshId": [
            "D000069476"
      ],
      "InterventionMeshTerm": [
            "Linagliptin"
      ],
      "InterventionName": [
            "Linagliptin"
      ],
      "InterventionOtherName": [
            "Tradjenta"
      ],
      "InterventionType": [
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "DPP-4 Inhibitor",
            "Linagliptin",
            "SDF1-\u03b1"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "November 9, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "November 5, 2020"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "University of Nevada, Reno"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Reno"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States"
      ],
      "LocationFacility": [
            "University of Nevada School of Medicine"
      ],
      "LocationState": [
            "Nevada"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "89503"
      ],
      "MaximumAge": [
            "45 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Linagliptin and Mesenchymal Stem Cells: A Pilot Study"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "University of Nevada, Reno"
      ],
      "OrgStudyId": [
            "LING-1"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "University of Nevada School of Medicine"
      ],
      "OverallOfficialName": [
            "Brian Kirkpatrick, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 4"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "March 2, 2018"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "SDF1-\u03b1 (stromal cell-derived factor alpha) Concentration"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Blood will be collected on the first week and then biweekly for 12 weeks."
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Flow cytometry will be used to examine the state of monocytes to look for cells recently arrived from the bone marrow and to examine the polarization (pro-inflammatory vs. anti-inflammatory) of the monocytes",
            "Flow cytometry will be used.",
            "Flow cytometry will be used to detect CD271+ cells."
      ],
      "SecondaryOutcomeMeasure": [
            "DPP-4 (Dipeptidyl peptidase-4) Activity",
            "Monocyte State",
            "Absolute/Differential leukocyte count",
            "CD271+ cells"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Blood will be collected on the first week and then biweekly for 12 weeks.",
            "Blood will be collected on the first week and then biweekly for 12 weeks.",
            "Blood will be collected on the first week and then biweekly for 12 weeks.",
            "Blood will be collected on the first week and then biweekly for 12 weeks."
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "March 2, 2015"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "November 2020"
      ],
      "StdAge": [
            "Adult"
      ],
      "StudyFirstPostDate": [
            "May 13, 2015"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "May 8, 2015"
      ],
      "StudyFirstSubmitQCDate": [
            "May 8, 2015"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}